Acceleron Pharma Inc. (NasdaqGM:XLRN) will look for acquisitions. Acceleron Pharma Inc. has filed a Follow-on Equity Offering for $200 million. Acceleron Pharma intends to use the net proceeds from the offering to conduct clinical trials and associated activities with therapeutic candidates from its existing research pipeline and for general and administrative expenses (including personnel-related costs), potential future development programs, capital expenditures and working capital and other general corporate purposes, including potential acquisitions of rights to additional programs from third parties.